| INTRODUCTION
Antimicrobial resistance was declared by the World Health Organization (WHO) in 2014 as the greatest threat for human and veterinary medicine. 1 Equine medicine also is affected, as demonstrated by the recent publication of several case reports. 2, 3 Nevertheless, molecular and epidemiological data in this species remains scarce. 4 Since their domestication, horses mainly have been considered working animals or livestock, although more recently some also may be considered companion animals. Therefore, they represent a potential source of contamination by direct contact with their owners or through the food chain. Horses have been overlooked in the global approach to antimicrobial resistance. 5 Nevertheless, they received more antimicrobials per kilogram than did cattle in France in 2013. 6 Escherichia coli is present in the intestinal microbiota of mammals, being mostly commensal although some strains can be pathogenic.
Because of its ubiquity, frequent exposure to systemic antimicrobial treatment, and its great genomic plasticity, this bacterium is considered by the European Center of Disease Control as an excellent indicator for antimicrobial surveillance. 7 An important mechanism of resistance that can be found in E. coli is the production of extended spectrum β-lactamases (ESBL), AmpC cephalosporinases (AmpC), 5 or both, resulting in the enzymatic inactivation of β-lactams. The global prevalence of β-lactamase genes (eg, bla) has increased considerably over the last 30 years throughout the world, both in humans and in animals. This increase might be due to spatial dispersal of mobile genetic elements or high-risk clones or could arise from antimicrobial pressure. In horses, phenotypic resistance to ceftiofur (XNL) has been documented in foals 8 and in adults. 9 The ESBL gene variant bla CTX-M-1 is most often identified. 10 However, bla CTX-M-2 , bla CTX-M-9 , 11 bla CTX-M-15 , 12 and several variants of bla CMY also have been detected. 10 All these variants also have been found in other animal 10 species and in humans. 13 The gene bla CTX-M-15 is the most prevalent variant in humans because it disseminates through epidemic plasmids and high-risk E. coli clones, 14 such as the sequencetype ST131. The β-lactamase genes mostly are carried by plasmids, which also may convey resistance to other antimicrobial classes, thus conferring multidrug resistance (MDR). 15 Moreover, owning a horse is a risk factor for carriage of ESBL in humans, 16 highlighting potential concern for public health. The use of third-and fourth-generation cephalosporins marketed for veterinary medicine is authorized in horses in France, possibly enhancing the dissemination of ESBL/AmpC genes.
Antimicrobial resistance genes may coexist with virulence genes on the same plasmids in pathogenic bacteria. 17 Although E. coli is not considered an enteric pathogen in adult horses, extra-intestinal pathogenic E. coli (ExPEC) sporadically have been recognized as potential pathogenic agents in horses, 18 and the presence of virulence factors has been reported in E. coli isolated from horses. 19 The ExPEC are of public health concern because some isolates may be zoonotic. The presence of highly virulent and antimicrobial-resistant strains in the intestinal microbiota of horses could represent a risk for horse handlers because of the possibility of transmission through close contact. 20 No data is available on the presence of MDR or ESBL/AmpCproducing isolates and ExPEC in the healthy equine population in France. Our objective was to determine the prevalence of, and risk factors for, shedding MDR or ESBL/AmpC-producing E. coli isolates in horses. We characterized potential ESBL/AmpC isolates for antimicrobial susceptibility and the presence of virulence and ESBL/AmpCassociated resistance genes.
| MATERIALS AND METHODS

| Sampling
This work was part of a larger study on resistance to anthelmintics and antimicrobials in horses in France. Sampling details were described elsewhere. 21 Briefly, premises housing more than 40 horses, as mentioned in the French Horse and Riding Institute (IFCE) database, were contacted by telephone and selected on a voluntary basis.
For each breeding premises, a riding school within a radius of 50 km was recruited when available. At time of the study, we estimated the number of riding schools in the source population as 1600 and the number of breeding premises as 249 in the study area (only riding schools located in French departments including selected breeding premises were considered). To be included in the study, horses had to be >2 years old and considered healthy by the premises manager.
They also had to be present on the premises for >4 weeks before sampling and must not have received anthelmintic treatment within the last 2 months. On the premises, a convenience sample of horses was assembled based on accessibility.
At each premises, between 8 and 36 horses were sampled. Two grams of feces were obtained, either from the rectum or within 5 minutes of defecation and stored at 4 C up to 6 hours. On the collection day, 18 mL of 30% glycerol were added to each sample, and the samples were stored at −20 C before analysis.
A questionnaire was developed based on published risk factors in the horse. 22 It was administered on the farm during an interview with the manager. Questions were directed to the general manager of the premises and were always at the premises level. The questionnaire was written in French and is available on request. At the horse level, prevalence estimates were adjusted for sampling weights to consider the different sampling probabilities of premises (riding school versus breeding) and horses within each premises (ie, the proportion of horses sampled was not constant across all premises). For the estimation of CIs, variances were adjusted for stratification by type of premises (riding school versus breeding) and for clustering to consider potential nonindependence of horses sampled within the same premises. At the premises level, prevalence estimates also were adjusted for sampling weights (at the premises level only) and stratification. The Surveyfreq procedure of SAS 9.4 was used for estimation, based on the Taylor series method.
2.3 | Potential ESBL/AmpC producing E. coli collection: Culture, antimicrobial susceptibility testing, ESBL/AmpC and virulence gene identification, and descriptive statistics
Bacteria producing ESBL/AmpC may be shed in small quantities in healthy animals. 31 To improve detection sensitivity and permit more accurate estimation of the proportion of positive premises, 2 different approaches were used for enrichment with CRO. In the first approach, samples used to produce the indicator collection were processed.
After receipt at the Ecl and first incubation, plates were scraped and For all isolates in this collection, we looked for 5 β-lactamase resistance genes (bla SHV , bla TEM , bla CMY-2 , bla OXA , bla CTX-M ) by PCR multiplex (PCR and gene identification protocols described above).
The potential pathogenicity of ESBL/AmpC-producing isolates was determined based on the presence of virulence genes which define E. coli pathotypes in animals (Enterotoxigenic E. 
| Risk factors
Two outcome variables were defined: MDR and ESBL/AmpC status of premises. Putative risk factors from the questionnaire with P < .20
(likelihood ratio test) in univariable logistic regression analysis were selected for inclusion in a multivariable model for each outcome. Pairwise associations between these selected variables were assessed by χ 2 test. In the presence of significant association (P < .05), only 1 of Prevalence estimates of horses shedding isolates nonsusceptible to >1, 3, 5, 7, or 9 classes of antimicrobials, and premises housing these horses, are summarized in Table 1 . The prevalence of horses shedding, isolates nonsusceptible to ≥1 antimicrobial and MDR isolates was high (84.4% and 44.4%, respectively). A total of 79.7% of premises housed horses shedding MDR isolates. In addition, 7.6% of horses shed isolates nonsusceptible to 7 classes of antimicrobials.
| ESBL/AmpC collection
Twenty-nine percent (95% CI, 11.5-46.5) of premises housed horses that shed isolates nonsusceptible to CRO and thus belonging to the ESBL/AmpC collection. In the first approach, 195 samples from individual horses from 41 premises were tested, and we detected positive samples for 5 premises. In the second approach, 744 samples from the 41 premises were tested either in pools or individually. We detected positive samples for16 premises (including the 5 premises identified using the first approach).
Nonsusceptibility was observed for a wide range of antimicrobial classes among the 50 isolates of this collection originating from the 16 positive premises (Figure 3 ). Indeed, all isolates were nonsuscepti- 
| Risk factors
Risk factors were calculated for 38 premises, because 3 questionnaires were not filled out completely. Sixteen potential risk factors were identified from the questionnaire ( Table 2 ). All were dichotomous or categorical.
Five risk factors were considered for multivariate modeling (all P < .20 in univariable analysis) for the ESBL/AmpC outcome, but
"transportation" and "contact with wild life" were excluded because they were associated with "the number of persons taking care of the horses" and "activity," respectively. According to the multivariate model, the odds of being an ESBL/AmpC premises were 14.6 times higher (P = .03) among the riding schools compared to breeding premises, 9.6 times higher (P = .03) if the premises housed a horse that had been medically treated within the last 3 months and 35.7 times higher (P = .006) in premises where the staff consisted of >5 persons (Table 3 ). The Hosmer-Lemeshow goodness-of-fit analysis indicated that our model fitted the data (P = .6). Transportation was marginally but not statistically significant (P = .06) in the univariate analysis but was excluded from multivariable analysis.
The odds of being an MDR premises were 6.7 (95% CI 1.2-38. 
| DISCUSSION
We demonstrated that the fecal microbiota of healthy horses harbors MDR and ESBL/AmpC E. coli isolates. The prevalence of premises housing horses shedding ESBL/AmpC E. coli isolates (29.0%) is comparable to that found in pig farms in other European countries. 32 This finding is both surprising and worrisome because horses can be considered companion animals. 10 Until now, the focus concerning antimicrobial resistance in animals has been on food-producing animals. 7 These results suggest that companion animals, including horses, also are important in the persistence of antimicrobial resistance genes.
Ceftiofur is a wide-spectrum third-generation cephalosporin approved for use in veterinary medicine that is very well tolerated by horses. Thus, its common use by horse practitioners 33 may promote Left of the table: Prevalence estimates of healthy adult horses shedding E. coli isolates nonsusceptible to more than 1, 3, 5, 7, or 9 classes of antimicrobials and premises housing these horses based on the indicator collection results in a cross-sectional study of 132 horses, in 38 premises, in France in 2015.
Right of the table: Prevalence estimates of premises housing healthy adult horses shedding isolates nonsusceptible to more than 1, 3, 5, 7, or 9 classes of antimicrobial in the ESBL/AmpC collection, based on the ESBL/AmpC collection results in a cross-sectional study on healthy horses, in 38 premises, in France in 2015.
Abbreviations: AmpC, AmpC β-lactamase; CI, confidence interval; ESBL, extended spectrum β-lactamase; MDR, multidrug resistant; Prev, prevalence. In addition to CTX-M ESBLs, the AmpC resistance gene bla CMY-2 is frequently found in food production animals in North America, 35 but it also has been found in Europe. 36 To the best of our knowledge, this gene has not previously been identified in healthy horses, and this finding reinforces the idea that AmpC genes may spread through the healthy animal population.
The ESBL/AmpC genes often are carried by MDR plasmids, which play a key role in their dissemination. 15 The high prevalence of ESBL/AmpC and MDR E. coli isolates observed in our study may be explained by the combination of the presence of such plasmids and antimicrobial pressure. Nevertheless, their mobile genetic elements, such as transposons and conjugative plasmids, and their ability to disseminate, should be investigated further. 13 Our approach of examining an indicator E. coli collection identified extensive drug resistance in E. coli in the intestinal microbiome of healthy horses in France, as previously observed in the United Kingdom. 4 The large amount of nonsusceptibility to AMP in the indicator collection could be explained by the frequent use of penicillin in equine medicine.
Acquired resistance to quinolones and fluoroquinolones is a result of the appearance of chromosomal mutations. Generally, the mutations appear in sequence and involve the genes gyrA (coding for the gyrase) and parC (coding for a subunit of the topoisomerase). The first mutation confers resistance to quinolones and the combination of the 2 mutations confers resistance to fluoroquinolones. Hence, nonsusceptibility to NAL generally is considered a predictor for fluoroquinolone treatment failure. 37 The finding in the indicator collection that >55% of premises featured this type of resistance suggests that ENR should be used with caution in horses.
Although we detected nonsusceptibility to third-generation cephalosporins in the indicator collection, none of the isolates carried tested ESBL/AmpC genes, suggesting that other ESBL/AmpC genes may be present in the population, (eg, bla OXA , bla PER , bla GES-1 , and bla VER-1 ) or other mechanisms of resistant to cephalosporins may be present (eg, an efflux pump). These other mechanisms would less likely be transmissible by mobile elements but also could account for treatment failure when using cephalosporins and therefore could still have an impact on the health of horses.
In the indicator collection, we detected viable E. coli in only 68% of the fecal samples. This viability rate is low compared to other published studies in healthy horses, 4 and compared to internal data available in our laboratory. Some E. coli isolates may have been lost during shipping. This issue questions the validity of the indicator collection results, but if it had any effect on the results it would have underestimated resistance. Indeed, antimicrobial resistance has a fitness cost, 38 and resistant isolates should have died first. Nevertheless, the level of resistance we found in the indicator collection, based only on E. colipositive samples, is comparable to that of other studies. 4 Therefore, we do not believe shipping had considerable influence on the results of the indicator collection.
Our results showed that medication represented a risk factor for ESBL/AmpC-positive premises. Antimicrobial treatment already has been identified as a risk factor at the individual level in other studies. 22 Although our results pertain to the premises level, we could hypothesize that medically treated horses are more likely to shed ESBL/AmpC isolates. Based on this information, we could suggest isolating horses that are medically treated or at least implementing appropriate biosecurity measures. As an example, limiting contact between treated and healthy horses and handling healthy horses before treated horses might be beneficial to limit antimicrobial gene dissemination. More longitudinal studies are needed to establish the duration of shedding in nonhospitalized horses and to develop more accurate recommendations. Nevertheless, based on other studies, 39, 40 the isolation of the horses should be for at least 2 weeks.
The finding that the number of persons taking care of horses influences the presence of ESBL/AmpC genes or the presence of MDR isolates has not been documented previously, to our knowledge.
Although more studies are needed to confirm such an association, considering that this information is easy to obtain, it could be helpful for elaborating guidelines to improve the health of horses. For example, it could help horse practitioners to define "at-risk" populations and justify the performance of antimicrobial susceptibility testing more frequently.
Riding schools also seem to be more at risk, as compared to breeding premises, for the presence of ESBL/AmpC genes. This risk factor is relevant because riding schools are an interface with the general population. This finding could provide the impetus to set up prevention measures to limit dissemination of ESBL/AmpC genes and MDR isolates.
Appropriate recommendations could include washing hands after touching horses or limiting contact between horses and infants at this type of premises, although further studies are needed to quantify the risk of transmission from horses to humans, and reciprocally.
Our study has some limitations. First, horses within a premises
were not selected randomly. However, we have no reason to believe that this selection process would have biased our results, considering that the people in charge of field sampling were blinded to the outcome status and drug use history of the horses. In addition, CIs for odd ratios were wide because of the small sample size of premises. Based on these results, it is not possible to compare the strength of association among the identified risk factors, and this low precision should be considered in interpreting the impact of these risk factors in the horse population. Small sample size also limited the statistical power of our study, and thus true associations with risk factors might have been missed.
Finally, because many risk factors were tested, some risk factors may have been statistically significant based on chance alone, and thus more studies should be conducted to confirm these associations.
In conclusion, we found a high prevalence of ESBL/AmpC genes and MDR isolates in the microbiota of healthy horses. Surveillance of ESBL/AmpC gene dissemination and quantification of MDR isolates would be beneficial to characterize the nature and extent of the risk they represent, with the aim of limiting their transmission among horses, but also to other species including humans and to the environment.
